Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuan Xiao ZhuCSChang‐Xin ShiKHKevin A. Hay

Discussion

Loading...

Member takes

Overview

This research demonstrates how pomalidomide alters T cell activation and antitumor activity in high tumor burden multiple myeloma, indicating its role in increasing exhaustion markers.

Key Points

  • To evaluate the effects of pomalidomide on memory BCMA CAR-T cells in contexts of high versus low tumor burden in multiple myeloma.
  • Generated murine anti-BCMA.CD28 CAR-T cells using T lymphocytes from hCRBN+ mice.
  • Evaluated tumor killing ability using flow cytometry in low and high tumor burden settings with various treatments.
  • Assessed CAR-T cell phenotype and activation markers post-treatment.
  • In low tumor burden, CAR-T cells effectively killed tumors regardless of pomalidomide addition.
  • In high tumor burden, pomalidomide diminished CAR-T cell killing and expansion, increasing exhaustion markers.
  • Exogenous IL-2 exacerbated the effects of pomalidomide, leading to CAR-T apoptosis.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d678https://doi.org/10.1182/blood-2025-5728
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease2024 · 11 citations
  2. 2The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  3. 3Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study2025
  4. 4Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation2025 · 1 citations
  5. 5Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma2025